SAN FRANCISCO, June 2, 2016 /PRNewswire/ -- Nektar
Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice
President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice
President & Chief Financial Officer of Nektar. Mr.
Nicholson has served as the Chief Financial Officer of Nektar since
2007. Mr. Labrucherie has served as Senior Vice President,
General Counsel and Secretary of Nektar since 2007.
"I am very pleased to announce these two well-deserved
promotions on Nektar's Executive Committee," said Howard W. Robin, President & CEO of
Nektar. "Both John and Gil have played an integral role in
Nektar's growth and development over the past eight years.
John has a strong record of performance and financial leadership
within Nektar and he brings over thirty years of experience in the
pharmaceutical industry to the newly-created role of Senior Vice
President & Chief Operating Officer at Nektar."
"Gil has demonstrated exceptional business acumen and strong
leadership skills during his tenure at Nektar and I am delighted
that he will now bring his insight and expertise to the position of
Senior Vice President & Chief Financial Officer," Robin
continued.
Mr. Nicholson, in the newly-created role of Senior Vice
President & Chief Operating Officer, will be responsible for
leading global business and corporate development, marketing,
quality assurance, and Nektar project management for the company's
partnered programs and wholly-owned pipeline candidates.
Over the tenure of his career, Mr. Nicholson has held key senior
leadership roles in the areas of operations, marketing, sales and
corporate strategy. Prior to joining Nektar, Mr. Nicholson served
in a number of leadership roles at Bayer Schering Pharma AG,
including Vice President, Corporate Development and Treasurer of
Schering Berlin Inc., President of Schering Berlin Insurance
Company, President of Bayer Pharma Chemicals Inc., and President of
Schering Berlin Capital Corporation.
In his new role as Senior Vice President & Chief Financial
Officer, Mr. Labrucherie will be responsible for leading the
company's finance and accounting teams, information technologies
and services, logistics, and will continue to provide
oversight for all legal functions, including intellectual
property. Mr. Labrucherie has held several senior leadership
positions with increasing responsibility at Nektar since
2005. Prior to joining Nektar, from October 2000 to September
2005, Mr. Labrucherie was Vice President of Corporate
Development at E2open, Inc., where he was responsible for global
corporate alliances and merger and acquisition activity. Prior to
E2open, he was the Senior Director of Corporate Development at
AltaVista Company, an Internet search company, where he was
responsible for merger and acquisition transactions. Mr.
Labrucherie began his career as an associate in the corporate
practice of the law firm of Wilson Sonsini
Goodrich & Rosati and Graham & James (DLA Piper
Rudnick). Mr. Labrucherie received his J.D. from the
University of California Boalt Hall
School of Law, where he was a member of the California Law Review
and Order of the Coif, and received his B.A. from the University of California, Davis.
About Nektar Therapeutics
Nektar Therapeutics has a robust R&D pipeline and portfolio
of approved partnered medicines in oncology, pain, immunology and
other therapeutic areas. In oncology, Nektar is developing
NKTR-214, an immuno-stimulatory CD122-biased agonist, that is in
Phase 1/2 clinical development for patients with solid tumors.
ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I
inhibitor, is being developed for patients with advanced
breast cancer and brain metastases and is partnered with Daiichi
Sankyo in Europe. In the area of pain, Nektar has an
exclusive worldwide license agreement with AstraZeneca for
MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral
peripherally-acting mu-opioid receptor antagonist (PAMORA)
medication for the treatment of opioid-induced constipation (OIC),
in adult patients with chronic, non-cancer pain. The product is
also approved in the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. NKTR-181, a wholly owned mu-opioid analgesic
molecule for chronic pain conditions, is in Phase 3 development. In
hemophilia, Nektar has a collaboration agreement with Baxalta for
ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting
PEGylated Factor VIII therapeutic approved in the U.S. and
Japan for patients over 12 with
hemophilia A. In anti-infectives, the company has two
collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for
non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3
for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for
Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C and Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Media Contacts:
Nektar Therapeutics:
Jennifer Ruddock
415-482-5585
Pure Communications:
Rachel Hutman
301-801-5540
rachel@purecommunicationsinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-executive-management-promotions-300279029.html
SOURCE Nektar Therapeutics